MiraDx, a molecular diagnostics company, uses unique microRNA-based biomarkers to personalize cancer treatment and avoid toxicity. Our first test, PROSTOX™, identifies germline variants in prostate cancer patients indicating increased risk of late GU toxicity following SBRT. With this information, the safest course of therapy may be selected.